Citius Oncology

Citius Oncology Current Liabilities

Current Liabilities of Citius Oncology (CTOR) as of Nov 22, 2026.

Current Liabilities

-USD

Last updated:

Current Liabilities of Citius Oncology is 2026 - USD. Current Liabilities of Citius Oncology was 2025 32.70 M USD. It decreases by % lower compared to the previous year.

The Citius Oncology Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2021
0.00 USD
Jan 1, 2022
31,800.00 USD
Jan 1, 2023
2.05 M USD
Jan 1, 2024
32.70 M USD
The Citius Oncology Current Liabilities history
YEARCurrent LiabilitiesYoY
32.70 MUSD+1,498.42%
2.05 MUSD+6,333.33%
31,800.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Citius Oncology Stock analysis

What does Citius Oncology do? Citius Oncology, Inc. develops and commercializes targeted oncology therapies, with its lead product candidate LYMPHIR for treating persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein that targets IL-2 receptors on cancer cells, inhibiting protein synthesis and causing cell death. The company focuses on relapsed or refractory cutaneous T-cell lymphoma (CTCL) patients after at least one prior systemic therapy, with the product indicated for Stage I-III disease. Citius Oncology, Inc. is a pharmaceutical company engaged in developing and commercializing targeted oncology therapies, with LYMPHIR as its primary product. The company's lead candidate targets CTCL, a rare non-Hodgkin lymphoma, and is designed for patients who have failed prior systemic treatments. The therapeutic mechanism involves binding to IL-2 receptors, delivering diphtheria toxin fragments to inhibit protein synthesis within cancer cells. The company's commercial strategy centers on LYMPHIR, which is positioned for relapsed or refractory CTCL patients requiring additional treatment options. LYMPHIR's mechanism of action specifically targets IL-2 receptors on cancer cells, leading to cell death through inhibition of protein synthesis. This targeted approach differentiates the product in the oncology therapy market for rare lymphoma subtypes. Citius Oncology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Citius Oncology stock

On Eulerpool you can find the complete historical development of Current Liabilities Citius Oncology since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Citius Oncology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Citius Oncology

All Key Metrics — Citius Oncology